explore -WSS

explore

author：comprehensive 2025-09-07 21:54:06 - browse：51151

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Reframing the conversation around gain

hotspot

WSS

Florida babysitter arrested over hot car death, authorities say

How Brent Saunders' Allergan experiment failed

What we know about the American soldier detained in North Korea

The biotech scorecard for the 2nd quarter: 12 industry events to watch

Biden, Billy Joel, Elton John lead tributes for Tony Bennett after singer's death at 96

New chart reveals military’s vast involvement in Operation Warp Speed

focus

explore

focus

As demand for Covid shots wanes, Moderna seeks its next success

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

New air purifier tech could be key to improving indoor air quality

Why the advice to take all your antibiotics may be wrong

Hollywood unions extend contract negotiations for actors

Why you get paid to donate plasma but not blood

BioMarin wins approval for gene therapy to treat hemophilia A

Biden, Billy Joel, Elton John lead tributes for Tony Bennett after singer's death at 96

Tori Bowie and the unacceptable rates of Black maternal death

Robert Kennedy Jr.'s presidential campaign attracts GOP

explore

Why Marc Tessier

DeSantis says Trump could've 'come out more forcefully' during Jan. 6

Prosecutors say FTX founder Sam Bankman

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

Listen: BridgeBio's big week & Lilly's Alzheimer's data

Study: Hearing aids may slow cognitive decline in those at risk

focus

explore

hotspot

focus